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Abstract A 52-year-old woman experienced sudden onset
of double vision due to a right abducens nerve palsy and
was diagnosed as having a pituitary macroadenoma that
invaded into the right cavernous sinus. Otherwise, she was
asymptomatic despite marked elevation of ACTH (293 pg/
ml) and cortisol (24.6 μg/dl) levels. The patient underwent
transsphenoidal surgery followed by γ-knife radiosurgery
(GKR), which healed the diplopia and ameliorated the
hypercortisolemia. The excised tumor was diffusely stained
for ACTH with a high (15%) Ki-67 labeling index. Early
tumor recurrence occurred twice thereafter, producing right
lower cranial nerve palsies with petrosal bone destruction at
8 months and an ipsilateral oculomotor nerve palsy at
12 months after GKR; all palsies resolved completely with
the second and third GKRs. Hypercortisolemia worsened
rapidly soon after the third GKR, and the patient developed
marked weight gain, hypokalemia, and hypertension.
Multiple liver lesions were incidentally detected with
computer tomography and identified as metastatic pituitary
tumor on immunohistochemistry. An ACTH-producing
adenoma should be followed carefully for early recurrence
and/or metastatic spread when the tumor is an invasive
macroadenoma with a high proliferation marker level. The
unique aggressive behavior and high potential for malig-
nant transformation of this case are discussed.
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Introduction
Pituitary carcinoma is a rare disorder accounting for 0.1–
0.5% of pituitary adenomas [1–4]. It is believed that
pituitary carcinomas arise from the transformation of
benign invasive macroadenomas [1–4], and the process of
this transformation takes place slowly [1]. A large majority
of pituitary carcinomas preserves a capacity for producing
anterior pituitary hormones [1–4], most notably ACTH and
prolactin. However, a definite distinction between pituitary
carcinoma and adenoma is impossible on the basis of
endocrinological, neuroradiological, and histological
criteria. The presence of CNS and/or distant metastases is
a prerequisite to establishing the diagnosis of this clinical
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DOI 10.1007/s12022-010-9144-5entity [1–4]. The most common is corticotroph carcinoma,
representing 42% of pituitary carcinomas [1–4], and 53
cases of corticotroph carcinoma have been described in the
English literature so far [5–45]. At the time of diagnosis, 32
(60%) of the 53 cases presented with symptoms and signs
of chronic hypercortisolemia characteristic of Cushing's
disease [5–9, 12–18, 20–22, 27–32, 34, 35, 38, 39, 43],
while 15 (28%) of the 53 cases developed these features
6 months to 12 years after an initial presentation as a
pituitary mass compressing the surrounding tissues [10, 11,
19, 23–26, 33, 36, 37, 39, 40, 42, 44, 45]. Although very
rarely, silent corticotroph carcinoma has also been recog-
nized by the presence of metastatic lesions in the absence of
clinical features associated with chronic hypercortisolemia
[27, 41]. A case of corticotroph carcinoma, which displayed
aggressive behavior resulting in multiple cranial nerve
palsies, invasive petrosal bone destruction, and liver
metastasis, is reported. This carcinoma presented initially
as an invasive macroadenoma causing double vision and
asymptomatic Cushing's disease, despite active hormone
production.
Case Presentation
A 52-year-old Japanese woman suddenly developed double
vision on the way to her office and was referred to our
university hospital by an ophthalmologist. She gained
10 kg in weight after menopause at the age of 50 years.
On physical examination, the patient's height was 151 cm,
and her weight was 63.5 kg, with a body mass index of
27.8 kg/m
2. Blood pressure was 120/78 mmHg. The patient
presented with no signs indicative of Cushing's syndrome,
such as moon face, truncal obesity, buffalo hump, purple
striae cutis, skin atrophy, or hirsutism. Neurological
examination was unremarkable except for a right abducens
nerve palsy. Past and family histories were unremarkable.
She had a history of two normal deliveries at ages 26 and
28 years. Routine blood tests revealed no abnormalities in
serum electrolytes, lipid profile, or glucose level.
Magnetic resonance imaging (MRI) revealed a pituitary
macroadenoma (height 22 mm; width 25 mm; depth
21 mm) that extended suprasellarly compressing the optic
chiasm, infrasellarly into the sphenoid sinus, and laterally
invading into the right cavernous sinus (Fig. 1a and b). On
gadolinium-enhanced T1-weighted coronal images, tumoral
invasion into the right cavernous sinus was evident at its
inferior portion along the inferior arterial wall of the
intracavernous internal carotid artery (ICA; Fig. 1b) and at
its middle portion through a space between the intra- and
supracavernous ICAs (Fig. 1a). Goldman's visual field test
was unremarkable. Endocrine investigation with the use of
the IRMA kit (Mitsubishi Chemical Yatron, Tokyo, Japan)
for ACTH and the TFB RIA kit (IMMUNOTEC, Prague,
Czech Republic) for cortisol measurement revealed a
concomitant elevation of morning ACTH (293 pg/ml;
normal range, 7.4–55.7 pg/ml) and cortisol (24.6 μg/dl;
normal range, 4.0–18.3 μg/dl) levels in blood and a
complete loss of the diurnal change in both hormones
(Table 1). Both elevated ACTH and cortisol levels did not
respond to an intravenous injection of a 100-μgd o s eo f
human corticotropin-releasing hormone (CRH; Sumitomo
Pharmaceutical Co. Ltd, Osaka, Japan) or to orally
administered low-dose (1 mg) or high-dose (8 mg) dexa-
methasone sodium phosphate in an overnight suppression
test (Table 1). For the hormonal systems other than the
ACTH-cortisol axis, growth hormone response to
L-arginine hydrochloride (30 g) infusion was impaired,
with a peak value of 0.12 μg/L (normal range, >3.0 μg/L).
Basal gonadotropins were diminished below normal post-
menopausal levels, while baseline prolactin and thyroid
function were normal. The search for mass lesions
producing ACTH ectopically within the thoracic and
abdominal cavities with computed tomography (CT) was
negative. The patient's double vision worsened progres-
sively, and the patient underwent transsphenoidal surgery
8 days after the first visit. Histologically, the excised
specimens were typical pituitary adenoma on hematoxylin–
eosin staining (Fig. 2a) and were diffusely immunostained
with mouse monoclonal anti-human ACTH antibody (Dako
UK Ltd, Cambridgeshire, UK; Fig. 2c), consistent with
ACTH-producing adenoma. The adenoma showed strong
nuclear pleomorphism, hyperchromasia, and enlarged nucleoli
(Fig. 2a), but it did not exhibit Crooke's hyaline change in the
cytoplasm, a histological feature characteristic of Crooke cell
adenoma. Mitotic figures were not observed. Up to 15% of
tumor cells were positively stained for a proliferation marker,
Ki-67 antigen, with mouse monoclonal anti-human MIB-1
antibody (Dako UK Ltd.; Fig. 2e).
Following the transsphenoidal surgery, morning ACTH
decreased to 47.9 pg/ml, accompanied by a decline in
cortisol to 2.9–4.5 μg/dl (Fig. 3). In an overnight
dexamethasone suppression test, however, serum cortisol
was not suppressed to a normal level of <1.0 μg/dl with the
high 8-mg dose. There was residual tumor in the right
cavernous sinus on MRI. The abducens nerve palsy
remained, though improved, leaving a moderate degree of
double vision with lateral gaze to the right. Two months
postoperatively, the patient was treated with γ-knife radio-
surgery (GKR; marginal dose, 25 Gy; maximum dose,
50 Gy) using the Leksell Gamma Knife Model C with
automatic positioning system (Elekta Instruments AB,
Stockholm, Sweden) [46], which ameliorated diplopia
completely by 3 months (Fig. 3). Eight months after
GKR, ACTH and cortisol increased to 244 pg/ml and
26.9 μg/dl, respectively, and the patient developed a
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cranial nerve palsies on the right side. Recurrence of the
tumor was detected with bone CT (Fig. 1c) and high-
resolution MRI within the right cavernous sinus at a site not
previously irradiated but not within the sella. The recurrent
tumor invaded destructively into the whole right petrosal
bone and destroyed the jugular foramen (Fig. 1c). One
month later, the second GKR (marginal dose, 15 Gy;
maximum dose, 30 Gy) was carried out, resulting in
complete disappearance of the lower cranial nerve palsies
within 1 month and normalization of the cortisol but not the
ACTH level (Fig. 3). Three months after the second GKR,
ACTH and cortisol rose to 146 pg/ml and 20.5 μg/dl,
respectively, and the patient again developed double vision,
but this time with left lateral gaze due to the right
oculomotor palsy. Recurrence of the tumor was again
identified with MRI in the superior–posterior part of the
right cavernous sinus (Fig. 1d), and 1 month after the
appearance of double vision, the patient received the third
GKR (marginal dose, 15 Gy; maximum dose, 30 Gy). The
diplopia resolved completely within 1 month, and cortisol
declined to an upper normal level of 16.1 μg/dl, but the
elevated ACTH remained unchanged (Fig. 3).
Four months after the third GKR, both ACTH and
cortisol began to rise rapidly, and 3 months later, they
reached unusually high levels of 534 pg/ml and 52.0 μg/dl,
respectively (Fig. 3). The patient's condition deteriorated,
accompanied by rapid weight gain (7 kg), generalized skin
pigmentation, severe hypokalemia (2.8 mEq/L), and hyper-
tension (170/110 mmHg), all of which were uncontrollable
Fig. 1 Radiographic presentation of a pituitary invasive macro-
adenoma in a patient who presented with multiple cranial nerve
palsies at different stages. Upper two films are conventional
gadolinium-enhanced T1-weighted 3-mm coronal slices (a, b), 6 mm
apart in an anterior to posterior direction, at initial presentation with a
right abducens nerve palsy. Arrows indicate cavernous sinus invasion.
Lower two images are axial (c) and coronal (d) images of contrast-
enhanced, 1-mm slices of bone CT at the time of lower cranial nerve
palsies (c) and T1-weighted, 2-mm slices of high-resolution MRI at
the time of a right oculomotor nerve palsy (d), both obtained under
stereotactic conditions [46]. The recurrence occurred twice within the
right cavernous sinus but not within the sella: at the first recurrence
the tumor destructively invades the petrosal bone and has destroyed
the jugular foramen (arrow)( c), and at the second, the tumor is seen to
have recurred at the superior–posterior portion of the cavernous sinus
(d). Color line-circled areas indicate the area irradiated with the same
dose of GKR; the outer area was irradiated at a lower dosage
Table 1 ACTH and cortisol measurement
Diurnal change Overnight dexamethasone suppression test Human corticotropin-releasing hormone (CRH) test
Time of day (h) Dose Time (min)
8:00 23:00 1 mg 8 mg 0 30 60 90
ACTH (pg/ml) 293 307 307 258 270 321 310
Cortisol (μg/dl) 24.6 36.2 35.8 29.0 26.2 30.9 30.2
12 Endocr Pathol (2011) 22:10–17with administration of spironolactone (50–100 mg/day) and
metyrapone (1.5–2.25 g/day) and supplementation with
slow-release potassium chloride (1.8–7.2 g/day; Fig. 3).
Because ACTH and cortisol levels continued to increase,
reaching extremely high levels of 654 pg/ml and 84.7 μg/
dl, respectively (Fig. 3), bilateral adrenalectomy was
planned as a therapeutic option. Abdominal CT at
24 months postoperatively to evaluate the status of adrenal
hypertrophy identified multiple space-occupying lesions in
the liver. Percutaneous needle biopsy gave negative results;
only necrotic tissues were obtained. The patient underwent
partial right-lobe hepatectomy [47], which removed all
hepatic lesions and led to reduction of serum cortisol to
25.9–28.8 μg/dl and normalization of hypokalemia (Fig. 3).
The excised hepatic lesions were histologically very similar
to the in situ pituitary adenoma in terms of nuclear
pleomorphism, increased nuclear chromatin, and prominent
nucleoli on hematoxylin–eosin staining (Fig. 2b). On
immunohistochemistry, the liver lesions were positive for
ACTH (Fig. 2d) and showed a remarkably high Ki-67
labeling index (Fig. 2f) with a value (35%) approximately
2.4 times higher than that (15%) of the primary tumor. In
addition, the in situ adenoma retrospectively immunos-
tained with monoclonal mouse antibody to p53 protein
(Dako UK Ltd) was strikingly positive (Fig. 2g). Following
abdominal surgery, both the hypertension and hypokalemia
Fig. 2 Photomicrographs of the
histological and immunohisto-
chemical features of the primary
pituitary tumor and the metasta-
sized liver tumor. Pituitary
tumor: a, c, e, and g; liver
tumor: b, d, and f. Both pituitary
and liver tumors show nuclear
pleomorphism, hyperchromasia,
and enlarged nucleoli (arrow
heads) on hematoxylin–eosin
staining, but neither tumor
shows mitotic figures (a, b).
There is diffuse cytoplasmic
ACTH immunostaining in both
tumors (c, d). Numerous tumor
cell nuclei are positive for Ki-
67, and the proportion of cells
with positive Ki-67 staining
accounts for 15% and 35% of
the primary (e) and metastasized
(f) tumor cells, respectively. Im-
munoreactive nuclear protein
p53 examined in the primary
pituitary tumor is stained in
almost all cells (g). Original
magnification ×400
(a, b), ×200 (c–g)
Endocr Pathol (2011) 22:10–17 13became medically controllable, and the patient's condition
was improving. Two months later, the patient died of septic
shock of unknown etiology.
Discussion
Pituitary carcinoma cannot be diagnosed before it develops
metastatic spread. The metastasis usually takes place within
the CNS to the cerebral cortex, cerebellum or cerebello-
pontine angle, brainstem, and spinal cord, or outside the
CNS to the liver, lymph nodes, bone, lung, and other
tissues [1–4]. In the absence of metastasis, it seems
necessary to attempt screening for those pituitary tumors
that might have an aggressive potential to transform into
carcinomas, although there is no practical clinical guideline
for their screening at present.
In 1997, Pemicone et al. classified adenohypophysial
tumors with respect to their aggressive potential and
described seven tumor characteristics required for pituitary
carcinoma [27]. The present case fulfilled all of the
characteristics that they described except for the presence
of mitosis: high Ki-67 immunoreactivity (15%), positive
p53 immunoreactivity, macroadenoma tumor size (2 cm),
gross invasion (proven by surgery), metastasis (liver), and
high blood hormone levels (ACTH and cortisol). In 2004,
the WHO introduced for pituitary tumors a new adenoma
entity termed atypical adenoma, which was designated as
an invasive tumor that exhibits an elevated mitotic index, a
Ki-67 labeling index greater than >3%, and extensive
nuclear staining for p53 immunoreactivity [48, 49]. This
definition denotes an aggressive potential for atypical
adenoma and the possibility of its future malignant
transformation. Atypical adenoma differs from carcinoma
only in the lack of metastasis. In keeping with the WHO
classification in 2004, Kaltsas et al. proposed in 2005 that
atypical tumors and those with a Ki-67 labeling index
greater than 10%, regardless of p53 immunostaining,
should be followed for early recurrence and/or development
of metastases [2]. The pituitary tumor of the present patient
fulfills the definition of the atypical adenoma introduced by
the WHO, except for the presence of mitosis, and is
consistent with the adenomas with a very high Ki-67
labeling index described by Kaltsas. Although there was no
mitosis in either the primary or metastasized tumor in the
present patient, it has been reported that mitoses were not
demonstrated in all pituitary tumors, i.e., positive in 21.4%
of invasive pituitary adenomas and 66.7% of pituitary
carcinomas [50]. Nonetheless, this cannot explain why the
primary adenoma cells did not show mitosis despite
expressing Ki-67 immunoreactivity in a very high propor-
tion. The cell cycle-specific Ki-67 antigen may not always
reflect all of the proliferating abilities of individual
adenomas that are turning over at different rates. Otherwise,
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Fig. 3 Clinical course as a function of time (months) after trans-
sphenoidal surgery. Upper panel shows sequential change in blood
ACTH and cortisol levels along with the timing (arrows)o f
therapeutic interventions that included transsphenoidal surgery
(TSS), γ-knife radiotherapy (GKR), and partial right-lobe hepatectomy
(Hepatex). The occurrence and resolution of cranial nerve palsies are
shown by black bars, in which the width indicates the duration of
palsy and the height indicates its severity. Broken and straight lines
indicate the upper normal limit of cortisol (18.3 μg/dl) and ACTH
(55.7 pg/ml), respectively. Shown over the upper panel are medi-
cations with daily dose in parentheses and their duration of use and
dosage in black bars. Lower panel shows the same time course for
serum potassium concentration with a broken line indicating the lower
limit of normal (3.4 mEq/L)
14 Endocr Pathol (2011) 22:10–17mitoses might have been obscured, though present, by
tissue processing or technical artifacts.
The latency period from the diagnosis of pituitary tumor
to the demonstration of metastasis varied considerably
among patients with corticotroph carcinomas [5–45], which
probably reflects the difference in the speed at which
individual pituitary adenomas transform into carcinoma. In
the 53 reported patients with corticotroph carcinomas
[5–45], the mean (±SE) latency period that we calculated
was 93±10 months (range, 3–360 months). The latency
period of the present patient was 24 months, which in the
order of latency length, was ranked as the fourth shortest.
No doubt, the latency period would have shortened if
abdominal CT, which detected hepatic metastases, had been
performed at an earlier stage. Such clinically rapid
progression of the disease, together with twice-repeated
early recurrence within the cavernous sinus, is highly
suggestive of an aggressive nature of the primary tumor
from the beginning of its clinical manifestation.
The aggressive, even malignant, nature of the tumor
might be supported by its high radiosensitivity, as
evidenced by rapid resolution of cranial nerve palsies
within 1–3 months after GKR. Three additional, unique
behaviors of the present tumor became evident on neuro-
logical and radiological examinations. The first was a
transient cystic enlargement of the irradiated residual tumor
that was incidentally recognized on MRI 1 month after the
first GKR. The second was the occurrence of the lower
cranial nerve palsies that caused swallowing difficulty and a
husky voice, and the third was destructive bone invasion
involving the unilateral whole petrosal bone, which was
detected on bone CT at the time of the lower cranial nerve
palsies. We have never observed any of these findings in a
series of several hundreds of pituitary adenoma patients
whom we treated with GKR. There is no description on
clinical features of atypical adenoma because it was defined
as a pathological, but not clinical, entity intermediate
between adenoma and carcinoma. The present tumor
pathologically accords well with atypical adenoma except
absence of mitosis, and hence its unusual behaviors
associated with repeated local recurrence within the
cavernous sinus could represent some clinical features of
atypical adenoma. It is likely that the patient's tumor, which
initially manifested as a clinically invasive macroadenoma
or pathologically as an atypical adenoma, subsequently
underwent malignant transformation presumably triggered
by the surgery and/or irradiation, a main mechanism
currently postulated to underlie the development of pitui-
tary carcinoma (1–4).
The reason for initial lack of glucocorticoid excess
symptoms may require some explanation. It might in part
be due to partial cortisol resistance of unknown etiology,
because the patient did not develop such hypercortisolemic
signs/symptoms as systemic pigmentation and hypertension
with hypokalemia until the last few months before death, at
which time serum cortisol increased to an extraordinarily
high level in parallel with ACTH. It is unlikely that the
patient's adenoma secreted a biologically inactive, C-
terminally extended, “big” ACTH [51]. First, the IRMA
used for our ACTH measurements does not recognize this
high-molecular-weight form of ACTH-related peptide.
Second, a closely parallel change in ACTH and cortisol
throughout almost the entire clinical course favors the view
of tumor-secreted ACTH as a biologically active peptide.
Consistent with the present patient, a substantial propor-
tion of previously reported patients with corticotroph
carcinoma did not present initially with Cushing's disease.
Of the 53 reported patients, including 34 women and 19
men, only 32 subjects were diagnosed as having Cushing'
syndrome or disease at initial presentation [5–9, 12–18, 20–
22, 27–32, 34, 35, 38, 39, 43]. The remaining 21 cases
were endocrinologically asymptomatic, except for one case
of galactorrhea–amenorrhea syndrome [25], and presented
with the pituitary mass compressing the adjacent tissues
[10, 11, 19, 23, 24, 26, 27, 33, 36, 37, 40–42, 44, 45]:
visual disturbance in 13 cases, headache in one case, and
visual impairment plus headache in five cases (symptoms
not described in one case [39]). These 21 hormonally
asymptomatic tumors, which were initially diagnosed as
non-functioning adenomas, can be divided into two
subgroups on the basis of the subsequent clinical course.
One subgroup consisted of 15 adenomas that developed
characteristic features of Cushing's disease 73±12 months
(range, 6–144 months) after initial diagnosis [10, 11, 19,
23–26, 33, 36, 37, 39, 40, 42, 44, 45]. Of these 15
adenomas, only five tumors underwent initial immunohis-
tochemical examination, and all were positive for ACTH,
indicating that these 5 adenomas were silent corticotroph
adenomas at the initial presentation. Notably, 12 of the 15
adenomas metastasized within 1–2 years after manifesting
as Cushing's disease, which suggests the possibility that
these metastasized adenomas had already undergone ma-
lignant transformation at the time of their clinical manifes-
tation as Cushing's disease. The other subgroup consisted of
the remaining six of the 21 adenomas that were all initially
diagnosed as silent corticotroph adenoma with ACTH
immunostaining and continued to be clinically silent until
they caused systemic or craniospinal metastasis [27, 41].
It is likely that marginally hypercortisolemic or even
eucortisolemic but endocrinologically abnormal subjects
have been mixed in with these initially asymptomatic
patients, because subjects with Cushing's disease often
have upper normal levels of baseline ACTH and/or cortisol
in blood. This is in contrast with prolactinomas, in which
blood prolactin levels increase proportionally with the size
of tumors, and macroadenomas usually have prolactin
Endocr Pathol (2011) 22:10–17 15values more than ten times higher than the normal upper
limit, thereby not requiring any dynamic test for diagnosis
[1–4, 52]. In clinically asymptomatic or subclinical Cush-
ing's disease, however, it is often difficult to make an
accurate diagnosis only with baseline cortisol and/or ACTH
levels without measuring 24-h urinary free cortisol output
or performing appropriate diagnostic tests, such as an
overnight dexamethasone suppression test to demonstrate
the abnormal glucocorticoid feedback regulation or deter-
mination of the morning and midnight cortisol levels to
identify the abnormal diurnal rhythm of the ACTH-cortisol
axis. The use of such diagnostic tests in patients with
invasive macroadenoma will decrease the chance of
misdiagnosing asymptomatic patients with Cushing's dis-
ease as having a non-functioning pituitary adenoma.
In conclusion, this is the first case of pituitary carcinoma
in our university hospital over the last 30 years, which is in
accordance with the rarity of this clinical entity. The
patient's tumor differed from common invasive macro-
adenomas, clinically with repeated early recurrence and
immunohistochemically with an extraordinarily high Ki-67
labeling index. Rapid aggressive progression of the disease
from initial presentation suggests that the patient's pituitary
tumor might have emerged de novo as a corticotropinoma
with high potential for malignant transformation. In our
clinical experience, non-functioning adenomas, the majority
of which is represented by gonadotropin-producing adeno-
mas, rarely exhibit a high degree of cavernous sinus
invasion, while often showing prominent suprasellar exten-
sion. “Non-functioning” adenomas, if they exhibit marked
parasellar invasion, should be screened for adenomas of
non-gonadotroph lineage. It is important to emphasize that
all patients with invasive macroadenoma should be
screened for Cushing's disease with an appropriate diag-
nostic test even if they are hormonally asymptomatic or
eucortisolemic, and if they indeed represent Cushing's
macroadenoma, they should be carefully followed for the
future development of corticotroph carcinoma.
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